IL92374A - Skin test and AIDS test kit - Google Patents
Skin test and AIDS test kitInfo
- Publication number
- IL92374A IL92374A IL9237489A IL9237489A IL92374A IL 92374 A IL92374 A IL 92374A IL 9237489 A IL9237489 A IL 9237489A IL 9237489 A IL9237489 A IL 9237489A IL 92374 A IL92374 A IL 92374A
- Authority
- IL
- Israel
- Prior art keywords
- envelope protein
- accordance
- hiv
- hiv envelope
- protein
- Prior art date
Links
- 238000012360 testing method Methods 0.000 title claims description 34
- 230000002163 immunogen Effects 0.000 claims abstract description 21
- 238000002347 injection Methods 0.000 claims abstract description 12
- 239000007924 injection Substances 0.000 claims abstract description 12
- 230000028993 immune response Effects 0.000 claims abstract description 4
- 230000008961 swelling Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims abstract 15
- 241000282412 Homo Species 0.000 claims abstract 2
- 101710091045 Envelope protein Proteins 0.000 claims description 27
- 101710188315 Protein X Proteins 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 241000238631 Hexapoda Species 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 241000701447 unidentified baculovirus Species 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 101800000385 Transmembrane protein Proteins 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 8
- 239000007864 aqueous solution Substances 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 17
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract description 15
- 230000009385 viral infection Effects 0.000 abstract description 4
- 238000001514 detection method Methods 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 description 21
- 208000031886 HIV Infections Diseases 0.000 description 21
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 8
- 230000005951 type IV hypersensitivity Effects 0.000 description 8
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 8
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 241000714195 Aids-associated retrovirus Species 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 201000005655 esophageal candidiasis Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27419788A | 1988-11-21 | 1988-11-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL92374A0 IL92374A0 (en) | 1990-07-26 |
| IL92374A true IL92374A (en) | 1994-02-27 |
Family
ID=23047193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9237489A IL92374A (en) | 1988-11-21 | 1989-11-20 | Skin test and AIDS test kit |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0370573B1 (fr) |
| JP (1) | JPH02262527A (fr) |
| KR (1) | KR900007384A (fr) |
| CN (1) | CN1043081A (fr) |
| AT (1) | ATE126706T1 (fr) |
| AU (1) | AU630129B2 (fr) |
| BR (1) | BR8905851A (fr) |
| CA (1) | CA2003300A1 (fr) |
| DE (1) | DE68923932T2 (fr) |
| DK (1) | DK582689A (fr) |
| IL (1) | IL92374A (fr) |
| LV (1) | LV10203B (fr) |
| NO (1) | NO894614L (fr) |
| ZA (1) | ZA898833B (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
| EP1545575A4 (fr) | 2002-09-19 | 2006-04-05 | Us Gov Health & Human Serv | Polypeptides p. ariasi polypeptides p. perniciosus et methodes d'utilisation |
| ES2447843T3 (es) | 2002-10-29 | 2014-03-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polip�ptidos de Lutzomyia longipalpis y m�todos de uso |
| EP1606419A1 (fr) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systemes et procedes pour accroitre la production de proteines et de lait chez des bovins laitiers |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| WO2005049794A2 (fr) | 2003-11-13 | 2005-06-02 | University Of Georgia Research Foundation, Inc. | Procedes de caracterisation du virus de la bursite infectieuse |
| WO2005112544A2 (fr) | 2004-02-19 | 2005-12-01 | The Governors Of The University Of Alberta | Polymorphismes du promoteur de la leptine et utilisations correspondantes |
| RS51324B (sr) | 2005-04-25 | 2010-12-31 | Merial Ltd. | Vakcine protiv nipah virusa |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| EP3147296A1 (fr) | 2005-11-14 | 2017-03-29 | Merial, Inc. | Thérapie génique pour traiter l'insuffisance rénale |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| MX2010012069A (es) | 2008-05-08 | 2010-12-14 | Merial Ltd | Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena. |
| EP2414386B1 (fr) | 2009-04-03 | 2016-01-27 | Merial Limited | Vaccins aviaires transportés par le virus de la maladie de newcastle |
| AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
| EP2611460B1 (fr) | 2010-08-31 | 2016-10-05 | Merial, Inc. | Vaccins contre le virus herpétique à base de vecteurs du virus de la maladie de newcastle |
| AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
| WO2012090073A2 (fr) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Procédés et compositions pour prédire la sensibilité à la chimiothérapie |
| EP2694678A2 (fr) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux |
| US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| WO2012149038A1 (fr) | 2011-04-25 | 2012-11-01 | Advanced Bioscience Laboratories, Inc. | Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci |
| CA2837375C (fr) | 2011-06-01 | 2019-07-16 | Merial Limited | Administration sans aiguille de vaccins contre le vsrrp |
| US8895027B2 (en) | 2011-07-20 | 2014-11-25 | Merial Limited | Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
| MX350096B (es) | 2011-08-12 | 2017-08-25 | Merial Inc | Preservación asistida con vacío de productos biológicos, en particular de vacunas. |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| WO2013033092A2 (fr) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Antigènes de poil de streptococcus suis |
| WO2013093629A2 (fr) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Vaccins modulaires, procédés et compositions qui y sont liés |
| WO2013138776A1 (fr) | 2012-03-16 | 2013-09-19 | Merial Limited | Nouveaux procédés pour fournir une immunité de protection à long terme contre la rage chez des animaux, basés sur l'administration d'un flavivirus défectueux en termes de réplication, exprimant la rage g |
| ES2711878T3 (es) | 2012-03-20 | 2019-05-08 | Merial Inc | Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma |
| EP2958586B1 (fr) | 2013-02-21 | 2018-09-05 | Boehringer Ingelheim Vetmedica GmbH | Protéines h5 du virus de la grippe h5n1 pour utilisation en tant que médicament |
| HK1216006A1 (zh) | 2013-03-12 | 2016-10-07 | Boehringer Ingelheim Animal Health USA Inc. | 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法 |
| JP6395855B2 (ja) | 2014-04-03 | 2018-09-26 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | ブタ流行性下痢ウイルスワクチン |
| WO2016073410A1 (fr) | 2014-11-03 | 2016-05-12 | Merial, Inc. | Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux |
| ES3050936T3 (en) | 2015-06-23 | 2025-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof |
| TWI799365B (zh) | 2015-08-31 | 2023-04-21 | 德商百靈佳殷格翰維美迪加股份有限公司 | 用於先天性痙攣症之瘟疫病毒疫苗 |
| US20170072042A1 (en) | 2015-09-16 | 2017-03-16 | Boehringer Ingelheim Vetmedica, Inc. | Salmonella choleraesuis-salmonella typhimurium vaccines |
| CA3036310A1 (fr) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | Nouveau vaccin contre la grippe porcine |
| WO2018057441A1 (fr) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | Vecteurs d'adénovirus canin |
| NZ751966A (en) | 2016-09-20 | 2023-03-31 | Boehringer Ingelheim Vetmedica Gmbh | New promoters |
| MX2019003161A (es) | 2016-09-20 | 2019-05-27 | Boehringer Ingelheim Vetmedica Gmbh | Nuevo sitio de insercion orf70 de ehv. |
| US10485866B2 (en) | 2016-11-03 | 2019-11-26 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus |
| PT3534939T (pt) | 2016-11-03 | 2023-04-20 | Boehringer Ingelheim Vetmedica Gmbh | Vacina contra parvovírus porcino e vírus da síndrome reprodutiva e respiratória porcina e métodos da sua produção |
| EA201991762A1 (ru) | 2017-01-30 | 2020-01-23 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Вакцины против коронавируса свиней |
| US11179457B2 (en) | 2017-07-12 | 2021-11-23 | Boehringer Ingelheim Animal Health USA Inc. | Senecavirus a immunogenic compositions and methods thereof |
| MX2020003071A (es) | 2017-09-23 | 2020-07-28 | Boehringer Ingelheim Vetmedica Gmbh | Sistema de expresion de paramyxoviridae. |
| WO2019092027A1 (fr) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Compositions immunogènes à base de sapelovirus et leurs utilisations |
| WO2019162294A1 (fr) | 2018-02-23 | 2019-08-29 | Boehringer Ingelheim Vetmedica Gmbh | Systèmes de vecteurs viraux recombinants exprimant des gènes de paramyxovirus félin exogènes et vaccins fabriqués à partir de ceux-ci |
| US11384365B2 (en) | 2018-03-19 | 2022-07-12 | Boehringer Ingelheim Vetmedica Gmbh | EHV with inactivated UL18 and/or UL8 |
| EA202092165A1 (ru) | 2018-03-19 | 2021-02-25 | Бёрингер Ингельхайм Ветмедика Гмбх | Новый ehv сайт инсерции ul43 |
| CN119488586A (zh) | 2018-03-26 | 2025-02-21 | 勃林格殷格翰动物保健美国有限公司 | 制备免疫原性组合物的方法 |
| KR102879825B1 (ko) | 2018-09-20 | 2025-11-03 | 베링거잉겔하임베트메디카게엠베하 | 변형된 pedv 스파이크 단백질 |
| US10905758B2 (en) | 2018-09-20 | 2021-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Intranasal vector vaccine against porcine epidemic diarrhea |
| CN115768784A (zh) | 2020-02-06 | 2023-03-07 | 勃林格殷格翰动物保健有限公司 | 用于检测抗弹状病毒抗体的多肽 |
| CA3195910A1 (fr) | 2020-10-05 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Proteine de fusion utile pour la vaccination contre les rotavirus |
| US20220160864A1 (en) | 2020-10-05 | 2022-05-26 | Boehringer Ingelheim Animal Health USA Inc. | Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422513D0 (en) * | 1984-09-06 | 1984-10-10 | Wellcome Found | Immunodiagnostic methods |
| US4879212A (en) * | 1986-04-02 | 1989-11-07 | United Biomedical Inc. | Peptide composition and method for the detection of antibodies to HTLV-III |
| IE872748L (en) * | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
| JPS63258575A (ja) * | 1986-12-15 | 1988-10-26 | レプリゲン コーポレーション | 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク |
| EP0279688B1 (fr) * | 1987-02-20 | 1997-04-16 | Genentech, Inc. | Méthodes et compositions pour l'utilisation de polypeptides env et anticorps anti-env de HIV |
| WO1989006276A2 (fr) * | 1988-01-08 | 1989-07-13 | Dpz Deutsches Primatenzentrum Gesellschaft Mbh | Retrovirus de primates du type hiv-2, vaccins, compositions diagnostiques et pharmaceutiques |
-
1989
- 1989-11-17 CA CA002003300A patent/CA2003300A1/fr not_active Abandoned
- 1989-11-20 AU AU45335/89A patent/AU630129B2/en not_active Ceased
- 1989-11-20 AT AT89202922T patent/ATE126706T1/de not_active IP Right Cessation
- 1989-11-20 DK DK582689A patent/DK582689A/da not_active Application Discontinuation
- 1989-11-20 IL IL9237489A patent/IL92374A/en not_active IP Right Cessation
- 1989-11-20 JP JP1303048A patent/JPH02262527A/ja active Pending
- 1989-11-20 KR KR1019890016798A patent/KR900007384A/ko not_active Withdrawn
- 1989-11-20 NO NO89894614A patent/NO894614L/no unknown
- 1989-11-20 DE DE68923932T patent/DE68923932T2/de not_active Expired - Fee Related
- 1989-11-20 EP EP89202922A patent/EP0370573B1/fr not_active Expired - Lifetime
- 1989-11-20 ZA ZA898833A patent/ZA898833B/xx unknown
- 1989-11-21 BR BR898905851A patent/BR8905851A/pt not_active Application Discontinuation
- 1989-11-21 CN CN89109558A patent/CN1043081A/zh active Pending
-
1993
- 1993-06-30 LV LVP-93-877A patent/LV10203B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL92374A0 (en) | 1990-07-26 |
| ZA898833B (en) | 1990-08-29 |
| KR900007384A (ko) | 1990-06-01 |
| DK582689D0 (da) | 1989-11-20 |
| EP0370573A3 (fr) | 1991-08-14 |
| EP0370573A2 (fr) | 1990-05-30 |
| CA2003300A1 (fr) | 1990-05-21 |
| LV10203A (lv) | 1994-10-20 |
| EP0370573B1 (fr) | 1995-08-23 |
| DK582689A (da) | 1990-05-22 |
| NO894614D0 (no) | 1989-11-20 |
| AU4533589A (en) | 1990-05-24 |
| DE68923932T2 (de) | 1996-01-11 |
| DE68923932D1 (de) | 1995-09-28 |
| ATE126706T1 (de) | 1995-09-15 |
| AU630129B2 (en) | 1992-10-22 |
| CN1043081A (zh) | 1990-06-20 |
| BR8905851A (pt) | 1990-06-12 |
| JPH02262527A (ja) | 1990-10-25 |
| NO894614L (no) | 1990-05-22 |
| LV10203B (en) | 1995-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0370573B1 (fr) | Test cutané et kit pour le dépistage du SIDA | |
| Hollinshead et al. | Skin-reactive soluble antigen from intestinal cancer-cell-membranes and relationship to carcinoembryonic antigens | |
| Nerup et al. | Antipancreatic cellular hypersensitivity in diabetes mellitus | |
| Clerici et al. | Exposure to Human Immunodeficiency Virus Type I-Specific T Helper Cell Responses before Detection of Infection by Polymerase Chain Reaction and Serum Antibodies | |
| Redfield et al. | Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost reduction strategy | |
| AU765050B2 (en) | Immunodiagnostics using particle delivery methods | |
| Mendonca et al. | Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis | |
| Gorse et al. | A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine | |
| JP3420245B2 (ja) | ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物 | |
| Viac et al. | Specific immunity in patients suffering from recurring warts before and after repetitive intradermal tests with human papilloma virus | |
| CZ295110B6 (cs) | Nové peptidy odvozené z lidského proteinu tepelného šoku 60 pro léčbu diabetes mellitus, farmaceutické přípravky, způsoby léčení a diagnostické soupravy | |
| Odaka et al. | Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men | |
| Torten et al. | A new leptospiral vaccine for use in man. II. Clinical and serologic evaluation of a field trial with volunteers | |
| Shawket et al. | Selective suprasensitivity to calcitonin-gene-related peptide in the hands in Raynaud's phenomenon | |
| Emmons et al. | A modified ELISA and Western blot accurately determine anti-human immunodeficiency virus type 1 antibodies in oral fluids obtained with a special collecting device | |
| Kelleher et al. | Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection | |
| Gorse et al. | Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration | |
| Khabbaz et al. | Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA | |
| Sommerville | Epidemic Kerato-Conjunctivitis—an adenovirus infection | |
| Bell et al. | Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1 | |
| Bussiere et al. | Preclinical safety assessment considerations in vaccine development | |
| Powell et al. | A rapid pertussis agglutination test | |
| Hildreth et al. | Alterations in delayed hypersensitivity produced by live attenuated measles virus in man | |
| Hyöty et al. | Cell‐mediated and humoral immunity to mumps virus antigen | |
| Craven et al. | Human Immunodeficiency Virus Infection in Pregnancy Epidemiology and Prevention of Vertical Transmission |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |